当前位置:首页>产品中心>单抗/多抗>Anti-Human RSPO2 Polyclonal Antibody|抗人RSPO2多克隆抗体(靶标:人R-脊椎蛋白2/R-spondin-2)

Anti-Human RSPO2 Polyclonal Antibody|抗人RSPO2多克隆抗体(靶标:人R-脊椎蛋白2/R-spondin-2)

  • 货号:RB9THA089014
  • 价格:面议
  • 点击:190

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human, Mouse
靶标R-spondin-2, RSPO2, Roof plate-specific spondin-2, hRspo2
免疫原E. coli - derived recombinant Human RSPO2 (Ser36-Gln243).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q6UXX9
背景信息

R-spondin-2 (RSPO2) is a ~28 kDa protein. Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. During embryonic development, plays a crucial role in limb specification, amplifying the Wnt signaling pathway independently of LGR4-6 receptors, possibly by acting as a direct antagonistic ligand to RNF43 and ZNRF3, hence governing the number of limbs an embryo should form.

1. de Lau, W. et al. (2011) Nature 476, 293-7. PMID: 21727895
2. Glinka, A. et al. (2011) EMBO reports 12, 1055-61. PMID: 21909076
3. Gong, X. et al. (2012) PloS one 7, e37137. PMID: 22615920
4. Szenker-Ravi, E. et al. (2018) Nature 557, 564-569. PMID: 29769720
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 499
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 433
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 354
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 514
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 592
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 590
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 288
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 335
Anti-Burosumab Non-Neutralizing Recombinant Antibody|抗布罗索尤单抗非中和重组抗体(靶标:布罗索尤单抗非中和抗体) 411
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 454
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 414
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 554
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 495
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 525
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 524
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 503
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 285
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 379
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 369
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 266
总计 33037 个记录,共 1652 页,当前第 1644 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00